𝔖 Bobbio Scriptorium
✦   LIBER   ✦

What's new: innovative concepts in inflammatory bowel disease

✍ Scribed by W. J. Sandborn

Book ID
109042573
Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
154 KB
Volume
8
Category
Article
ISSN
1462-8910

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Chemoprophylaxis of colorectal cancer in
Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: Current concepts
✍ Jonathan S. Levine; Robert Burakoff πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 82 KB

Ulcerative colitis and Crohn's disease both confer an increased risk of developing colorectal cancer. The use of 5-aminosalicylate as a remission-inducing agent has been long accepted. Its use as a potential chemoprophylactic agent has been proposed and is used by some practitioners. This review exa

New pathogenic paradigms in inflammatory
New pathogenic paradigms in inflammatory bowel disease
✍ Antonio Di Sabatino; Paolo Biancheri; Laura Rovedatti; Thomas T. MacDonald; Gino πŸ“‚ Article πŸ“… 2012 πŸ› John Wiley and Sons 🌐 English βš– 78 KB

Recent progresses in basic science have opened new pathogenic scenarios in inflammatory bowel disease. The T helper cell type (Th)1/Th2 paradigm has been outdated thanks to the advances in understanding the function of Th17 cells. Innate immunity, nonimmune cells, and defective tolerogenic mechanism

New steroids for inflammatory bowel dise
New steroids for inflammatory bowel disease
✍ Dr. Robert LΓΆfberg πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 700 KB

The antiinflammatory effects of glucocorticosteroids (GCS) in inflammatory bowel disease (IBD) are unsurpassed by those of any other type of drug, but the beneficial effects are often offset by troublesome, and sometimes irreversible, systemic side effects. Improved GCS have been developed with the